Background: Collection and reporting of adverse events (AEs) and their relatedness to study treatment, known commonly as attribution, in clinical trials is mandated by regulatory agencies (the National Cancer Institute and the Food and Drug Administration). Attribution is assigned by the treating physician using judgment based on various factors including patient's baseline status, disease history, and comorbidity as well as knowledge about the safety profile of the study treatments. We evaluate the patterns of AE attribution (unrelated, unlikely, possibly, probably, and definitely related to the treatment) in treatment, symptom intervention (cancer patients) and cancer prevention (participants at high risk for cancer) setting.
Introduction
Collection and reporting of adverse events (AEs) and their relatedness to study treatment, known commonly as attribution, in clinical trials is mandated by regulatory agencies (the National Cancer Institute (NCI) [1] and the Food and Drug Administration (FDA) [2] ). Attribution is assigned by the treating physician using judgment based on various factors including patient's baseline status, disease history, and comorbidity as well as knowledge about the safety profile of the study treatments. Based on the NCI Cancer Therapy Evaluation Program (CTEP) guidelines, attribution is categorized as not related, unlikely related, possibly related, probably related, and definitely related to study treatment. There is no clear consensus among clinicians on how to assign attribution and no clear guidance from the NCI or the FDA on this issue [1] [2] [3] .
Assignment of AE attribution is a complex process that typically involves multiple interactions between the treating physician, the nurse/clinical research assistant, and/or pharmacist. This adds considerable time and effort to the trial process. Mukherjee et al. [4] conducted 32 semi-structured interviews with medical oncologists and trial coordinators and found that many researchers used a similar strategy to assign attribution. However, it was felt that the process is done quickly without complete clinical or investigational data and tend to be highly subjective. Thomas et al. [5] showed a poor to moderate inter-rater reliability among physicians when assigning causality to AEs. Hillman et al. [6] showed in two multicenter randomized double-blind placebo-controlled treatment trials that nearly 50% of AEs in the placebo arm were reported as related to treatment (data from this study will be presented along with other trials in the next section).
In what follows, we provide an analysis of AE data from a number of double-blind placebo-controlled trials to better understand the phenomenon of AE attribution. Using randomized doubleblind placebo-controlled trials allows us to evaluate the pattern of AE attribution in a setting with minimal bias that is often caused by knowledge of treatment assignment. This is because the placebo arm of these randomized double-blind trials allows us to evaluate the accuracy of attribution assignment. If attribution assignment is truly accurate, we would expect to see close to 0% of AEs in the placebo arms classified as related to treatment. In some instances, placebo formulation can cause some side effects such as diarrhea but those would likely be very minimal. Furthermore, if attribution assignment is accurate, we would expect the percentage of patients with AEs reported as related to treatment in the active arm to be the same as the difference in the AE rates between the active arm and the placebo arm. We thus attempt to quantify the accuracy and value of attribution assignment in clinical trials in multiple settings: treatment, symptom control and prevention. Based on these observations, we provide possible alternatives to analyse AE data from randomized trials without collecting information on attribution (relationship to study treatment) of AEs.
Methods
Data. Overall, nine double blind placebo controlled randomized trials were included in this analysis (Table 1) [7] [8] [9] [10] [11] [12] [13] [14] [15] . Of these, two were treatment [7, 8] , two were symptom intervention [9, 10] , and 5 were cancer prevention studies [11] [12] [13] [14] [15] . A total of four phase III and five phase II studies were included encompassing a variety of tumor types: gastrointestinal stromal tumors (GIST), lung, breast, esophageal, and colorectal. A total of 2155 patients were included across these trials.
Analysis
Due to differences in trial setting, disease, and treatment, the individual trials were analysed separately within each category (treatment, symptom intervention and prevention). The following analyses were conducted for each trial. The proportions of patients with AE for all grades and for Grade 3 or above (3þ) were summarized by arm. The number of AEs and the proportion of AEs of Grade 3þ, and the proportion of AEs classified as related to the treatment were summarized by arm. The number of repeated AEs (defined as the total number of second or subsequent occurrences of an AE that occurred more than once in the same patient) was summarized. Percentage of repeated AEs whose attribution changed (from not related to any of unlikely related, 186 (92) 713 (354) 333 (165) 490 (163) 123 (30) 77 (36) 63 (30) 85 (41) 85 (22) possibly related, probably related, and definitely related, and similarly for all the other categories) over time, as well as whose relatedness changed (from possible, probable or definitely related to unlikely or not related, and vice versa) over time were summarized for the placebo arms. Since these are randomized double-blind placebo-controlled trials, the differences in the AEs rates between the active treatment arm and the placebo arm are unbiased estimators of the rate of toxicity. These differences serve as an empirical indicator of whether the active treatment itself causes additional AEs. The difference in AE rates between the treatment arm and the placebo arm was therefore calculated to provide the empirical attribution estimate. Percentage of physician over-or under-reporting of attribution in the treatment arm was estimated as the difference between the percent AE reported by physicians as related to the treatment and the empirical estimate divided by the empirical estimate.
Results

Observed patterns: treatment trials
In each of these trials (NCCTG 97-24-51 [7] and ACOSOG Z9001 [8] ), the distributions of AEs in the treatment and the placebo arms were strikingly similar (results are summarized in Table 2 ). The percentage of patients who experienced any AEs was 90% in both arms of the two trials, with 34% and 18% of patients experiencing events of Grade 3 or higher in the placebo arms of two trials, respectively. At the individual AE level, the percentages of reported Grade 3-5 AEs were also similar between the treatment and the placebo arms [7, 8] . The proportions of AEs deemed related (defined as possibly, probably, and definitely related) to treatment were also similar between arms. Of the AEs that were deemed related, between 75% and 85% were classified as possibly related. Our data showed that CAI (NCCTG 97-24-51) and Imatinib (Z9001) did not cause significant increase in toxicity. However, 60% of AEs across arms of NCCTG 97-24-51 were designated as at least possibly related to CAI and 62% of AEs in Z9001 were assigned at least possibly related to Imatinib. Clinician-assigned attribution over estimated the toxicity attributable to the treatment. It is worth noting that most of the AEs classified as related to treatment fall in the possible category ( Figure 1 ). From our conversations with investigators, many routinely classify AEs as possibly related to treatment while others only use this assignment category when they truly felt uncertain if the AEs were related to treatment.
Our data showed that nearly 50% of AEs in the placebo arms were classified as related to treatment and these percentages are close to what are reported for the treatment arm which indicates that attribution assignment is not an accurate process. Another factor that makes reliability of attribution questionable is that the attribution of the same AE that occurred multiple times in the same patient changed overtime. Importantly, attribution of 25% of the repeated AEs in NCCTG 97-24-51 and 18% in Z9001 changed from related to treatment to unrelated or vice versa.
Observed patterns: symptom intervention trials
Similar to the patterns observed in the two treatment trials, the distributions of AEs in the treatment and the placebo arms in the two symptom intervention trials (NCCTG 97-92-53 [9] and MC04CC [10] ) were very similar (results are summarized in Table 3 ). The percentages of patients experiencing any AEs were close to 90% in all arms and nearly 50% of patients experienced events of Grade 3 or higher. At the individual AE level, the percentages of Grade 3-5 AEs reported were also similar between the treatment and the placebo arms [9, 10] . The proportions of AEs deemed related (defined as possibly, probably, and definitely related) to treatment were also similar between arms. Of the AEs that were deemed related, >80% were classified as possibly related. Our data showed that Epoetin alfa (NCCTG 97-92-53) and iron supplement (MC04CC) did not cause significant increase in toxicity. However, 11% of AEs in the NCCTG 97-92-53 trial were designated as at least possibly related to Epoetin alfa and 25% of AEs in the MC04CC trial were assigned at least possibly related to Iron supplement. Again, most of the AEs classified as related to treatment fall in the possible category (Figure 1 ). Data in this setting again showed a high percentage of AEs in the placebo arms classified as related to treatment and these percentages are close to what are reported for the treatment arm and the attribution of 10% of the repeated AEs in NCCTG 97-92-53 and 17% in MC04CC changed from related to treatment to unrelated or vice versa.
Observed patterns: cancer prevention trials
In cancer prevention setting (MAYO 04-4-01 [11] , MAYO 10-15-03 [12] , MAYO 03-1-02 [13] , MAYO 06-8-01 [14] and MAYO 03-10-3 [15] ), the number of AEs reported was low and <7% were Grade 3-5 events (results are shown in Table 4 ). In three of the five trials included in our analysis, more AEs were reported in the placebo arm than in the intervention arm (MAYO 04-4-01 [11] , MAYO 03-1-02 [13] , and MAYO 03-10-3 [15] ). In the other two trials [12, 14] , more AEs were reported in the intervention arm. Again, we observe that the percentages of cases classified as related to treatment were much higher than the difference in AEs rates between the intervention and the placebo arm indicating that attribution assignment over estimated toxicity attributed to the intervention.
Similar to the pattern observed in the symptom intervention trials described earlier, except for the aspirin 81mg arm of the MAYO 04-4-01 trial [11] , the possibly related category accounts for 70-100% of all AEs classified as related to the intervention (Figure 1) . Although, in most of these trials, the percentages of AEs in the placebo arms classified as related to the intervention were lower than their respective intervention arms, these percentages were still much higher than expected (range 19-57%). The numbers of repeated AEs were small due to the low rates of AEs in these studies. For the trials with a higher number of repeated AEs, the attribution of 8-20% of these AEs changed overtime.
Discussion Notable observations
The main patterns consistently observed in all three trial settings include the following: (i) clinician-reported attribution tends to overestimate the rate of AEs related to treatment, (ii) a very high proportion of AEs reported as related to treatment were classified Figure 1 . Distribution of relatedness by arm for each trial.
as possibly related (Figure 1 ), (iii) a significant proportion of AEs in the placebo arm were incorrectly reported as related to treatment, and (iv) fatigue, nausea, vomiting, diarrhea, constipation, and neurosensory were common AEs over reported by clinician as related to treatment. There were very few under reported AEs and no pattern was detected.
Alternatives to attribution assignment
The data shown in this work along with previously published results from Hillman et al. [6] suggest that assignment of attribution to AEs is subjective and unreliable in various settings of cancer clinical trials including treatment trials, symptom intervention trials, and cancer prevention trials. Adverse event attribution is a contributing factor to the rising cost of clinical trials [16] . Collection of attribution data adds cost to clinical trials by adding an undue burden on the care team in clinical practice and can potentially impact patient care by interrupting treatment based on incorrect attribution. Some alternative approaches to assessing AE attributable to treatment that is more objective and more cost efficient are described below:
1. In randomized double-blind placebo-controlled trials, a simple way to assess toxicity related to treatment is to compare the frequencies and severity of various types of AEs reported for patients in the treatment arm to those in the placebo arm. Such a comparison can even ignore baseline or pre-existing symptoms since those may be unreliably collected and should be equally distributed in all treatment arms but for the play of chance. This is the same approach routinely used to compare other outcomes in clinical trials and suggested by Sargent and George [17] . We acknowledge that there are many different types of AEs and the number of events for some AEs can be small. Standard statistical methods with large sample inference might not be appropriate for analysis of rare events. However, careful examination of the differences in type, frequency, severity, and time when various AEs occur provides insight into the additional burden caused by the treatment. 2. Cleeland et al. [18] showed that 33% of patients reported three or more symptoms in the moderate to severe range at baseline. It is important to collect baseline AEs to distinguish treatment-related events from pre-existing conditions. It is also important to clearly report the definition, types, and collection schedule of AEs and provide comprehensive reports of all grade AEs. Ioannidis et al. [19] and Scharf and Colevas [20] provide some guidance for AE reporting. 3. AE can also be evaluated using time-to-event analysis methods as appropriate for the study objectives. If time to the first occurrence of specific AE is of interest, it can be analysed using models for competing risks data [21, 22] . If the rate of recurrent events is also of interest then methods for time-to-event analysis of multiple events of the same type is appropriate [23] . The complexity of AE data provides an opportunity for development of new approaches to analyse rare events and repeated events. 4. Another approach to understanding the additional toxicity attributable to the treatment is to assess AE from the patient perspective. Bent et al. [24] and Cleeland et al. [18] suggested collecting AEs using patient questionnaires. Patients report more AEs when a list of symptoms is presented compared to open-ended questions [18, 24] . The NCI Patient-reported outcome version of the CTCAE, called the PRO-CTCAE, has recently been validated [25] . It includes 124 items representing 78 symptomatic AEs. The PRO-CTCAE collects information on the frequency and severity of AEs. PRO-CTCAE can be administered alongside clinician reported CTCAE [26] . Change from not related to any of unlikely related, possibly related, probably related, or definitely related; and so on for each category.
c Change from possible, probable or definitely related to unlikely or not related, and vice versa.
It provides complementary assessment of the frequency and severity of AEs based on patient personal experience. PRO-CTCAE recall period can be modified as appropriate based on duration of treatment cycle. These additional data provide deeper understanding of toxicity burden caused by the treatment.
Our data show that attribution is subjective and unreliable in randomized double-blind placebo-controlled trials. In openlabel trials, including single-arm phase II, while we can hypothesize that there would be more bias leading to even more subjectivity in attribution assignment, our current analyses do not directly lend evidence for elimination of attribution in these trials. While assessment of causality can be learned from comparison with placebo arms in closely related indications from previous trials, we recommend caution and consideration of the difference in time trend, in patient populations, and potential concomitant treatments, between the current trial and previous trials when making comparison to ensure that the difference in AEs between the current trial and previous trials is solely due to the treatment under investigation.
Acknowledging that attribution in dose-finding phase I trials can be subjective, further evaluation is necessary prior to making a recommendation to eliminate attribution in these trials for the following reasons: (i) since treatment toxicity is the primary endpoint of phase I trials, we expect attribution to be more clearly defined and toxicity evaluation to be more thorough in these trials; (ii) phase I trials are often conducted in a few centers (and thus a more controlled setting) involving a small number of investigators, we expect less variability in attribution assignment; and (iii) an analysis by Eaton et al. [27] showed no association between dose and toxicity rate of unrelated AEs and a significant association between dose and the toxicity rate of AEs related to treatment suggesting that misattribution does not occur at a high rate in phase I dose-finding trials.
Conclusions
Our data along with other work in the literature confirmed that assigning causality to AE is a complex and costly process that produces unreliable and subjective outcome. In randomized double-blind placebo-controlled trials where data are available to objectively assess toxicity related to treatment, attribution assignment should be eliminated to lessen the burden for investigators and all parties involved in trial conduct. The subjectivity of attribution assignment is not due to the clinicians' ability to ascertain causality but rather due to the lack of complete data at the time of assignment and the multifaceted nature of adverse symptoms. In the modern era where combination of drugs is standard treatment of cancer, it is even more difficult to determine which of the drugs being studied caused the AE. The same issues apply to studies with chemotherapy backbone or symptom intervention trials where the event can be attributed to the disease, the cancer treatment, or the treatment of other symptoms.
Objective assessment of AEs due to treatment can be achieved by well-designed trials with appropriately planned collection and analysis of AE data. Including baseline AE assessment provides additional information to determine whether an AE is newly developed after treatment initiation or a continuation of a preexisting event. Careful analysis of rare and repeated occurrence of AE data and collecting patient-reported AEs can provide a comprehensive picture of additional AE burden caused by treatment. 
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